Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company based in the United States. It focuses on developing product candidates that precisely target proteins critical to immune cell maturation and function. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is being evaluated in a multi-center Phase 1b/2 clinical trial for several conditions, including peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, solid tumors, and asthma. Additionally, the company is developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor in Phase 2 trials for first-line renal cell cancer, and mupadolimab (CPI-006), a humanized monoclonal antibody in Phase 1 trials for non-small cell lung cancer.

Corvus Pharmaceuticals, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol CRVS. The trading currency for its shares is the US Dollar (USD). The company is headquartered in South San Francisco, California, and operates primarily in the United States.

Corvus Pharmaceuticals operates within the Healthcare sector and specifically in the Biotechnology industry. As a clinical stage biopharmaceutical company, it focuses on developing targeted therapies for immune-related diseases and cancers. Biotechnology companies like Corvus typically engage in research and development of novel drugs, often with a high risk and long development timeline before potential commercialization.

Corvus Pharmaceuticals, Inc. is headquartered in South San Francisco, California, United States. The company primarily serves the US market, as indicated by its focus on clinical trials conducted in the US and its licensing agreements with US-based institutions. Its research and development activities are centered in the US, and it aims to address medical needs in oncology and immunology.

Corvus Pharmaceuticals has three main product candidates in its pipeline. Soquelitinib (CPI-818) is a selective covalent inhibitor of ITK, currently in a Phase 1b/2 trial for multiple indications including peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, solid tumors, and asthma. Ciforadenant (CPI-444) is an oral small molecule antagonist of the A2A receptor in Phase 2 trials for first-line renal cell cancer. Mupadolimab (CPI-006) is a humanized monoclonal antibody in Phase 1 trials for non-small cell lung cancer. The company also has license agreements with Monash University for CXCR2 antibodies and with Vernalis for adenosine receptor antagonists, including ciforadenant, as well as with Scripps for mupadolimab.